Loading...
The care of patients with type I diabetes has come a long way, but the efficacy of new diagnostic and therapeutic technologies is rarely established in pregnant women. In an open-label randomized controlled trial, investigators from seven countries sought to address this gap by studying outcomes associated with continuous blood glucose monitoring (CGM) versus usual care in 215 women who were pregnant and 110 who were planning pregnancy.
Compared with women receiving usual care, pregnant women assigned to CGM experienced a 0.19% greater reduction in glycosylated hemoglobin (HbA1c) values between baseline (≤13 weeks and 6 days' gestation) and 34 weeks' gestation. In the GCM group, plasma glucose values were within the recommended range for a g…